Pharmaceuticals

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

A new FDA-approved powder form of a common blood pressure drug aims to solve a daily struggle for the elderly, children, and tube-fed patients.

Philip Morris International's upcoming Q1 2026 earnings will be a crucial test of its pivot from cigarettes, with all eyes on ZYN's growth and regulatory hurdles.

A new strategic deal for the Lasix ONYU device aims to secure its key ingredient, transforming heart failure care from the hospital to the living room.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

Following a major partnership, AST and Marchesini Group will showcase next-gen robotic filling and inspection tech, aiming to reshape sterile drug production.

With new top-tier executives, Danish biotech MinervaX is accelerating its quest to deliver the world's first vaccine against a leading cause of infant death.

As millions drive on common medications, a leading expert joins a national panel to address the silent, growing crisis on America's roadways.

With backing from AI leaders, Helical’s virtual lab aims to turn powerful models into reproducible drug discovery systems, tackling a key industry bottleneck.

Phase 3 data shows GTx-104 reduces key risks and improves outcomes for aSAH patients, positioning it as a potential new standard of care ahead of an FDA decision.

Biotech firm Genvor leverages its AI platform in a new partnership, aiming to fast-track novel peptides for anti-aging and weight loss to a booming market.

With its lead depression drug nearing Phase 3, AtaiBeckley faces investors to tackle the regulatory and commercial hurdles of psychedelic medicine.

Harrow partners with specialist LogiCare3PL for U.S. distribution, highlighting an industry shift towards agile, high-touch logistics for faster market access.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

BioTesserae's BTC-001, a novel immunotherapy, proves safe in early trials, paving the way for more affordable and accessible treatment for dogs.

FDA approves the first generic of a vital nutrition drug, granting Apotex a 180-day exclusive edge and signaling major cost savings for healthcare.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

A new report reveals a major gap in AI adoption as digital disruptors and generic GLP-1s force Canadian pharmacies to innovate or risk being left behind.